BioMedNewsBreaks Archive - Page 59 of 257

ThursdayDec 05, 2024 11:00 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Host Virtual Analyst & Investor Day on December 11

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for brain and central nervous system cancers, will host a Virtual Analyst & Investor Day on December 11 from 11:30 a.m. to 1 p.m. ET. The event will feature presentations by the company’s leadership team, including CEO John Climaco, Chief Medical Officer Dr. Sandra Silberman, and VP of Clinical Operations Zena Muzyczenko, alongside key opinion leaders Dr. Michael Weller, Dr. Samuel Goldlust, and Dr. Erin Dunbar. Discussions will focus on glioblastoma multiforme (“GBM”), updates on the clinical development of Berubicin, and regulatory strategies for the company’s second asset, TPI 287. A…

ThursdayDec 05, 2024 9:10 am

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) CEO Highlights Innovations in Neurodegenerative Drug Development on Today’s Marketplace

Annovis Bio (NYSE: ANVS), a leader in developing treatments for neurodegenerative diseases, was recently featured on Today’s Marketplace in an exclusive interview with Dr. Maria Maccecchini, Founder, President, and CEO. Dr. Maccecchini detailed Annovis Bio’s groundbreaking drug development targeting toxic proteins responsible for nerve cell damage in Alzheimer’s and Parkinson’s, as well as the company’s next-phase clinical trials. Emphasizing the broader impact of these diseases on caregivers as well as patients, Dr. Maccecchini shared insights into the meaningful progress Annovis Bio is making. The Today’s Marketplace feature continues to spotlight Annovis Bio’s leadership in addressing critical healthcare challenges, reinforcing its…

WednesdayDec 04, 2024 3:41 pm

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) CEO Shares Insight on Breakthrough Drug Showing Promise for Neurodegenerative Diseases

Annovis Bio (NYSE: ANVS) was featured in an interview with Today's Marketplace (“TMP”). The company’s Founder, President and CEO, Maria Maccecchini, PHD, and Scott Shipman, MD, MPH, Executive Director for Creighton University's Institute for Population Health, joined host Jane King to discuss clinical trials of a new drug that is showing promise for the treatment of neurodegenerative diseases like Alzheimer's (“AD”) and Parkinson's (“PD”) and their impact on population health. "We have over 7 million people with neurodegeneration in the United States, and it is a huge problem. We think of the patients, but we should also think of the…

TuesdayDec 03, 2024 3:47 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Showcases Platform ‘Designed to Unlock New Possibilities in Cancer Therapy’

Calidi Biotherapeutics (NYSE American: CLDI) is focused on discovering more effective treatments amid projections from the American Cancer Society that 2024 will be the first year ever to see two million people diagnosed with cancer. “Calidi Biotherapeutics’ RTNova (‘CLD-400’) is an innovative systemic antitumor enveloped virotherapy designed to unlock new possibilities in cancer therapy. The platform addresses challenges presented by untargetable and untreatable metastatic diseases and offers a possible potential transformative solution with wide-ranging applications,” reads a recent article. “The company shared key information about RTNova at two recent conferences: the International Oncolytic Virotherapy Conference (‘IOVC’) in Rotterdam, Netherlands, which…

TuesdayDec 03, 2024 3:30 pm

BioMedNewsBreaks — BioAdaptives Inc. (BDPT) Announces One-for-One Stock Dividend

BioAdaptives (OTC: BDPT) today announced that its board of directors approved a dividend to all common stockholders. According to the announcement, stockholders will receive matching shares for all of their owned shares on the record date. “This dividend is designed to acknowledge your steadfast belief in our vision and to reward you for standing by us as valued stakeholders,” said BDPT CEO James Keener. “This special dividend aligns with our dedication to enhancing shareholder value while reinforcing our focus on long-term growth and success. The additional shares you will receive signify our shared optimism for the future and our determination…

WednesdayNov 27, 2024 9:56 am

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Welcomes Dr. Jonathan Sadeh to Scientific Advisory Board

Scinai Immunotherapeutics (NASDAQ: SCNI) has appointed Dr. Jonathan Sadeh to its Scientific Advisory Board, where he will support the advancement of the company’s IL-17 program and VHH antibody pipeline. Dr. Sadeh brings over 20 years of drug development experience, including senior leadership roles at Bristol-Myers Squibb, where he led programs in immunology, cardiovascular, and neuroscience, and was instrumental in the approval of Sotyktu for psoriasis. With a background in pulmonary and critical care from Harvard Medical School and a focus on innovative therapies addressing unmet medical needs, Dr. Sadeh expressed enthusiasm for Scinai’s bio-better approach and collaborations with institutions like…

TuesdayNov 26, 2024 1:10 pm

BioMedNewsBreaks – Modular Medical Inc. (NASDAQ: MODD) Announces Pricing of $8.2M Public Offering

Modular Medical (NASDAQ: MODD) is an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design. The company recently announced its pricing of an underwritten public offering of 5,450,573 shares of its common stock. The offering was led by existing institutional investors, including the company’s largest shareholder, Manchester Explorer, L.P., and is managed by Jeb Besser, Modular Medical's CEO. Gross proceeds to the company are expected at approximately $8.2 million, with shares of common stock each being sold at a price to the public of $1.50. Titan…

MondayNov 25, 2024 1:25 pm

BioMedNewsBreaks — BioAdaptives Inc. (BDPT) to Proceed with Human Clinical Trial for Zeranovia(TM)

BioAdaptives (OTC: BDPT) today announced its receipt of approval for a human clinical trial of its weight management product, Zeranovia(TM). Approved by an Institutional Review Board, the trial will be managed and supervised by doctors in Las Vegas, Nevada. “According to data from the National Institutes of Health's Office of Dietary Supplements (‘ODS’), less than 1.0% of nutraceuticals sold in the United States undergo examination in human clinical trials,” said BioAdaptives CEO James Keener. “We are committed to supplying the highest quality products with provable scientific results. Zeranovia’s(TM) success is based on a high-protein blend of vitamins, minerals, and five…

MondayNov 25, 2024 11:04 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Progress in Pivotal Study of Berubicin for Glioblastoma Treatment

CNS Pharmaceuticals (NASDAQ: CNSP) announced updated results from its ongoing pivotal trial evaluating Berubicin, a novel anthracycline crossing the blood-brain barrier, against Lomustine in recurrent glioblastoma multiforme (“GBM”). Presented at the 29th Annual Meeting of the Society for Neuro-Oncology, the data show balanced patient demographics and safety profiles between the study arms, with Berubicin showing comparable adverse event rates and promising potential to improve overall survival (“OS”), the trial's primary endpoint. With enrollment completed at 252 patients, CNS expects to report primary analysis data in early 2025. Berubicin holds FDA Fast Track and Orphan Drug Designations, underscoring its significance in…

MondayNov 25, 2024 10:09 am

BioMedNewsBreaks — HealthLynked Corp. Completes $3 Million Cash Consideration from ACO Health Partners Sale

HealthLynked (OTCQB: HLYK) announced the receipt of $500,000 as part of its contractual share of shared savings generated by ACO Health Partners (AHP) during the 2023 performance period. This marks the final payment under the terms of the January 2023 sale of AHP, bringing the total gross proceeds to $3 million, including $750,000 from the initial sale and $1.75 million in participation-based payments. CEO Dr. Michael Dent highlighted the strategic value of the sale, enabling HealthLynked to focus on advancing its core healthcare technology and patient engagement solutions. To view the full press release, visit https://ibn.fm/dyOwj About HealthLynked Corp. HealthLynked…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Host Virtual Analyst & Investor Day on December 11

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) CEO Highlights Innovations in Neurodegenerative Drug Development on Today’s Marketplace

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) CEO Shares Insight on Breakthrough Drug Showing Promise for Neurodegenerative Diseases

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Showcases Platform ‘Designed to Unlock New Possibilities in Cancer Therapy’

BioMedNewsBreaks — BioAdaptives Inc. (BDPT) Announces One-for-One Stock Dividend

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Welcomes Dr. Jonathan Sadeh to Scientific Advisory Board

BioMedNewsBreaks – Modular Medical Inc. (NASDAQ: MODD) Announces Pricing of $8.2M Public Offering

BioMedNewsBreaks — BioAdaptives Inc. (BDPT) to Proceed with Human Clinical Trial for Zeranovia(TM)

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Progress in Pivotal Study of Berubicin for Glioblastoma Treatment

BioMedNewsBreaks — HealthLynked Corp. Completes $3 Million Cash Consideration from ACO Health Partners Sale

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search